Base to Base biotech podcast 23: Digitalisation in labs, and are fibroblasts the future of regenerative medicine?

This week, we have a wide-ranging conversation with Anna Codina, senior director strategy and business development at SciY (part of Bruker), as we discuss artificial intelligence, and digitalisation, and the effect on labs. We also chat with Fibrobiologics’ CEO Pete O'Heeron about fibroblast spheroid technology.Interview times:03:49 FibroBiologics21:26 SciYSciY on the path to digitalisationThis week, we have a wide-ranging conversation with Anna Codina, senior director strategy and business development at SciY (part of Bruker), as we discuss artificial intelligence, and digitalisation, and the effect on labs.SciY offers a vendor-agnostic digitalisation platform and a wide range of software solutions for research, development, and manufacturing, enabling workflow integration, automation, digital transformation, and AI readiness.SciY solutions integrate scientific instruments and automation hardware with their scientific data into a digital environment. Data is ingested, standardised, reused, and preserved according to the FAIR data principles, delivering maximum value with minimal effort and disruption.FibroBiologics and fibroblast spheroid technologyBased in Houston, Texas, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials.FibroBiologics holds more than 275 US and international patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer.The company is looking to create the next generation of medical advancement in cell therapy and tissue regeneration.To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]